[go: up one dir, main page]

PL1658292T3 - Pochodne triazolopirymidyny jako inhibitory kinazy 3 syntazy glikogenu - Google Patents

Pochodne triazolopirymidyny jako inhibitory kinazy 3 syntazy glikogenu

Info

Publication number
PL1658292T3
PL1658292T3 PL04766189T PL04766189T PL1658292T3 PL 1658292 T3 PL1658292 T3 PL 1658292T3 PL 04766189 T PL04766189 T PL 04766189T PL 04766189 T PL04766189 T PL 04766189T PL 1658292 T3 PL1658292 T3 PL 1658292T3
Authority
PL
Poland
Prior art keywords
inhibitors
glycogen synthase
synthase kinase
triazolopyrimidine derivatives
triazolopyrimidine
Prior art date
Application number
PL04766189T
Other languages
English (en)
Inventor
Eddy Jean Edgard Freyne
Christopher John Love
Ludwig Paul Cooymans
Nele Vandermaesen
Peter J J A Buijnsters
Marc Willems
Werner C J Embrechts
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PL1658292T3 publication Critical patent/PL1658292T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL04766189T 2003-07-16 2004-07-12 Pochodne triazolopirymidyny jako inhibitory kinazy 3 syntazy glikogenu PL1658292T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP0350310 2003-07-16
EP04766189A EP1658292B1 (en) 2003-07-16 2004-07-12 Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
PCT/EP2004/051455 WO2005012307A1 (en) 2003-07-16 2004-07-12 Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors

Publications (1)

Publication Number Publication Date
PL1658292T3 true PL1658292T3 (pl) 2008-01-31

Family

ID=34112425

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04766189T PL1658292T3 (pl) 2003-07-16 2004-07-12 Pochodne triazolopirymidyny jako inhibitory kinazy 3 syntazy glikogenu

Country Status (26)

Country Link
US (2) US7560458B2 (pl)
EP (1) EP1658292B1 (pl)
JP (1) JP2009514782A (pl)
KR (1) KR20060120393A (pl)
CN (1) CN100404536C (pl)
AP (1) AP2006003486A0 (pl)
AR (1) AR045698A1 (pl)
AT (1) ATE370142T1 (pl)
AU (1) AU2004260738B2 (pl)
BR (1) BRPI0412596A (pl)
CA (1) CA2531333A1 (pl)
DE (1) DE602004008303T2 (pl)
DK (1) DK1658292T3 (pl)
EA (1) EA010109B1 (pl)
ES (1) ES2290754T3 (pl)
IL (1) IL173139A (pl)
JO (1) JO2460B1 (pl)
MX (1) MXPA06000540A (pl)
NO (1) NO20060678L (pl)
NZ (1) NZ545058A (pl)
PA (1) PA8607001A1 (pl)
PL (1) PL1658292T3 (pl)
PT (1) PT1658292E (pl)
TW (1) TW200524935A (pl)
WO (1) WO2005012307A1 (pl)
ZA (1) ZA200600385B (pl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
DE60330466D1 (de) 2002-07-29 2010-01-21 Rigel Pharmaceuticals Inc VERFAHREN ZUR BEHANDLUNG ODER PRuVENTION VON AUTOIMMUNKRANKHEITEN MIT 2,4-PYRIMIDINDIAMIN-VERBINDUNGEN
CN100404536C (zh) * 2003-07-16 2008-07-23 詹森药业有限公司 作为糖原合酶激酶3抑制剂的三唑并嘧啶衍生物
PL1656372T3 (pl) 2003-07-30 2013-08-30 Rigel Pharmaceuticals Inc Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym
JP4607879B2 (ja) * 2003-08-15 2011-01-05 ノバルティス アーゲー 新生物疾患、炎症および免疫障害の処置に有用な２，４−ピリミジンジアミン
MXPA06002997A (es) * 2003-09-18 2007-02-08 Conforma Therapeutics Corp Novedosos compuestos heterociclicos como inhibidores- hsp90.
MX2007003321A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
JP4958785B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼインヒビターとしてのそれらの使用
AU2005286647A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
WO2006034441A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
MX2007003319A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
US7919496B2 (en) 2004-09-20 2011-04-05 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
AU2005286728A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
MX2007005159A (es) 2004-10-29 2007-06-26 Tibotec Pharm Ltd Derivados de pirimidina biciclicos inhibidores del vih.
WO2006076442A2 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives
CA2618646A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
ES2651349T3 (es) 2005-06-08 2018-01-25 Rigel Pharmaceuticals, Inc. Composiciones y métodos para la inhibición de la ruta JAK
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス，インコーポレイティド 神経発生のｇａｂａ受容体媒介調節
EP1991532B1 (en) 2006-02-24 2017-01-11 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
SG175609A1 (en) 2006-10-09 2011-11-28 Takeda Pharmaceutical Kinase inhibitors
EP2167497A2 (en) * 2007-06-29 2010-03-31 Sunesis Pharmaceuticals, Inc. Heterocyclic compounds useful as raf kinase inhibitors
CL2008001933A1 (es) * 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
BR112012029647A2 (pt) 2010-05-21 2016-08-02 Chemilia Ab novos derivados de pirimidinas
JP5886411B2 (ja) 2011-03-24 2016-03-16 ノビガ・リサーチ・エービーＮｏｖｉｇａ Ｒｅｓｅａｒｃｈ ＡＢ 新規のピリミジン誘導体
MX2014008864A (es) * 2012-01-28 2014-12-15 Merck Patent Gmbh Derivados de triazolo[4,5-d]pirimidina.
WO2013131609A1 (en) 2012-03-07 2013-09-12 Merck Patent Gmbh Triazolopyrazine derivatives
ES2614872T3 (es) 2013-03-05 2017-06-02 Merck Patent Gmbh Derivados de 9-(aril o heteroaril)-2-(pirazolilo, pirrolidinilo o ciclopentilo) aminopurina como agentes anticancer
AU2014224975B2 (en) * 2013-03-05 2017-09-14 Merck Patent Gmbh Triazolo(4,5-d)pyrimidine derivatives for the treatment of diseases such as cancer
WO2014180524A1 (en) 2013-05-06 2014-11-13 Merck Patent Gmbh Macrocycles as kinase inhibitors
CA2969587A1 (en) * 2014-12-05 2016-06-09 Centre National De La Recherche Scientifique (Cnrs) Compounds for treating cystic fibrosis
WO2017035528A1 (en) 2015-08-27 2017-03-02 Nantneuro, Llc Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau
WO2017156527A1 (en) 2016-03-11 2017-09-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase and janus kinase inhibitors for prevention of graft versus host disease
US20220133740A1 (en) 2019-02-08 2022-05-05 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5962594A (ja) * 1982-09-30 1984-04-10 Ss Pharmaceut Co Ltd ３，５―ジ置換―トリアゾロピリミジン誘導体
US20020040031A1 (en) * 2000-07-07 2002-04-04 Glasky Michelle S. Methods for prevention of accumulation of amyloid beta peptide in the central nervous system
US6737085B2 (en) * 2000-11-01 2004-05-18 Tokiwa Phytochemical Co., Ltd. Apocynum venetum extract for use as antidepressant
US7105532B2 (en) * 2000-12-19 2006-09-12 Smithkline Beecham Corporation Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors
CN100404536C (zh) * 2003-07-16 2008-07-23 詹森药业有限公司 作为糖原合酶激酶3抑制剂的三唑并嘧啶衍生物

Also Published As

Publication number Publication date
IL173139A (en) 2010-04-29
US20060205721A1 (en) 2006-09-14
ZA200600385B (en) 2007-05-30
BRPI0412596A (pt) 2006-09-19
AR045698A1 (es) 2005-11-09
ATE370142T1 (de) 2007-09-15
TW200524935A (en) 2005-08-01
PT1658292E (pt) 2007-10-25
EA010109B1 (ru) 2008-06-30
AU2004260738A1 (en) 2005-02-10
MXPA06000540A (es) 2006-03-30
DE602004008303T2 (de) 2008-05-08
WO2005012307A1 (en) 2005-02-10
EA200600258A1 (ru) 2006-06-30
NZ545058A (en) 2008-05-30
DE602004008303D1 (de) 2007-09-27
US20090036471A1 (en) 2009-02-05
CA2531333A1 (en) 2005-02-10
AP2006003486A0 (en) 2006-02-28
JP2009514782A (ja) 2009-04-09
US7560458B2 (en) 2009-07-14
EP1658292B1 (en) 2007-08-15
DK1658292T3 (da) 2007-11-12
ES2290754T3 (es) 2008-02-16
NO20060678L (no) 2006-02-10
KR20060120393A (ko) 2006-11-27
PA8607001A1 (es) 2005-05-10
CN100404536C (zh) 2008-07-23
EP1658292A1 (en) 2006-05-24
CN1823068A (zh) 2006-08-23
AU2004260738B2 (en) 2009-07-16
IL173139A0 (en) 2006-06-11
JO2460B1 (en) 2009-01-20

Similar Documents

Publication Publication Date Title
IL173139A0 (en) Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
HRP20180578T1 (hr) Pirolo[2,3-b]piridin-4-il-amini i pirolo[2m3-b]pirimidin-4-il-amini kao inhibitori janus kinaze
AP2048A (en) Diazepinoindole derivatives as kinase inhibitors
HRP20181912T1 (hr) Derivati pirolo[2,3-d]pirimidina kao inhibitori janus kinaze
IL172132A0 (en) Thienopyridone derivatives as kinase inhibitors
IL173380A0 (en) Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
IL165515A0 (en) Bisindolyl-maleimid derivatives as kinase inhibitors
IL173381A0 (en) 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
IL173200A0 (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
SI2395004T1 (sl) Derivati piro (2,3-b) piridina kot inhibitorji proteinske kinaze
IL167088A (en) Pyrazolopyrimidine derivatives as cyclin dependent kinase inhibitors
HK1071570A1 (en) Pyrazolopyrimidines as cyclin dependent kinase inhibitors
AU2003271566A8 (en) Pyrrolopyrazines as kinase inhibitors
AP2006003620A0 (en) Imidazopyrazine tyroshine kinase inhibitors
PL1644376T3 (pl) Pochodne pirolo[3,4-c]pirazolu aktywne jako inhibitory kinazy
EP1590333A4 (en) GLYCOGENE SYNTHASE KINASE 3BETA INHIBITOR, COMPOSITION AND PROCESS FOR PREPARING THE SAME
AU2003282976A1 (en) Inhibitors of glycogen synthase kinase 3
ZA200802690B (en) Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
AU2003254051A8 (en) Pyrazolopyrimidines as kinase inhibitors
IL172375A0 (en) Chinazoline derivatives as aurora kinase inhibitors
HK1071758A1 (en) Pyrazolopyridines as cyclin dependent kinase inhibitors
EP1638557A4 (en) INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3
SI1483265T1 (sl) Drivati purina kot inhibitoriji kinaze
SI1625126T1 (sl) Imidazo- in tiazolopiridini kot inhibitorji JAK3-kinaze
IL203601A0 (en) Pyrazolopyrimidines as cyclin-dependent kinase inhibitors